NCT00618527View on ClinicalTrials.gov

Combination Therapy Using Cellcept and Rebif in RRMS

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

31

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions

Multiple Sclerosis

Interventions

DRUG

mycophenolate mofetil (Cellcept)

1 gram po, bid

DRUG

human interferon beta 1a (Rebif)

44mcg sq injection every other day

Trial Locations (1)

43221

The Ohio State University Multiple Sclerosis Center, Columbus

Sponsors

Lead Sponsor

Collaborators (2)

All Listed Sponsors

collaborator

EMD Serono

INDUSTRY

collaborator

Pfizer

INDUSTRY

lead

Aaron Boster

OTHER

NCT00618527 - Combination Therapy Using Cellcept and Rebif in RRMS | Biotech Hunter | Biotech Hunter